Home/Filings/4/0002001011-25-000082
4//SEC Filing

Aryeh Jason 4

Accession 0002001011-25-000082

CIK 0000886163other

Filed

Sep 23, 8:00 PM ET

Accepted

Sep 24, 5:11 PM ET

Size

10.7 KB

Accession

0002001011-25-000082

Insider Transaction Report

Form 4
Period: 2025-09-23
Aryeh Jason
Director
Transactions
  • Sale

    Common Stock

    2025-09-23$170.41/sh4,418$752,85074,871 total
  • Sale

    Common Stock

    2025-09-23$170.96/sh4,628$791,22370,243 total
  • Sale

    Common Stock

    2025-09-23$171.92/sh954$164,01569,289 total
Holdings
  • Common Stock

    (indirect: Indirect)
    51,594
  • Common Stock

    (indirect: By Trust)
    5,025
Footnotes (4)
  • [F1]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $169.6625 to $170.6600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $170.6850 to $171.6050. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $171.7250 to $172.2400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.

Issuer

LIGAND PHARMACEUTICALS INC

CIK 0000886163

Entity typeother

Related Parties

1
  • filerCIK 0001376960

Filing Metadata

Form type
4
Filed
Sep 23, 8:00 PM ET
Accepted
Sep 24, 5:11 PM ET
Size
10.7 KB